Business
SeeThruEquity Initiates Coverage On Medical Marijuana, Inc. Investment Company AXIM Biotech (OTC: AXIM) With A Target Price Of $17.00
SeeThruEquity Initiates Coverage On Medical Marijuana, Inc. Investment Company AXIM Biotech (OTC: AXIM) With A Target Price Of $17.00.
About this update from Axim Biotechnologies, Inc.
[{"type":"text","content":"\n\n\n\nSeeThruEquity Initiates Coverage On Medical Marijuana, Inc. Investment Company AXIM Biotech (OTC: AXIM) With A Target Price Of $17.00\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nSeeThruEquity Initiates Coverage On Medical Marijuana, Inc. Investment Company AXIM Biotech (OTC: AXIM) With A Target Price Of $17.00\nPR Newswire\nSAN DIEGO, May 17, 2017\n\n\n\nSAN DIEGO, May 17, 2017 /PRNewswire/ -- Medical Marijuana, Inc. (OTC PINK:MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its investment company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM) received coverage initiation from SeeThruEquity, a leading independent equity research firm focused on smallcap and microcap public companies, with a price target of $17.00.\n\n\"We are thrilled to see a well respected Wall Street equities firm initiating coverage on AXIM Biotech,\" said Dr. Stuart Titus, President and CEO of Medical Marijuana Inc. (OTC: MJNA).  \"We have believed that AXIM would emerge as an up-and-coming biotech concern and quite excited about their cannabinoid research and pharmaceutical development activities.  It is thrilling to see the investment community taking notice of AXIM's emerging story and perceiving future value for investors.\"\n\nThe full research report is available here. Highlights from the report include:\n\nLarge market opportunityThe market for cannabis-based pharmaceutical and nutraceuticals is emerging and quickly growing. Indeed, legal cannabis is among the fastest growing industries in the United States, estimated at $7.1 billion in 2016, including both medical and recreational uses, according to a report by New Frontier and ArcView Market Research. Longer term, the market has been forecast by Cowen to be as much as $50 billion within ten years assuming federal legalization takes place in the United States. We note that progress towards legalization is likely to have an impact on the valuation and perception of Axim and all cannabis companies, however the company's strategy includes a global per...